COLLEGE STATION - More than 100 high paying jobs in the vaccine-making business could be coming to this area as a local company looks to expand.
News 3 looks at the economic incentive deal College Station City Council members will consider Thursday night and how the company could affect your health.
Kalon Biotherapeutics has been working on vaccinations and drug development here since 2012.
Now they hope to expand.
Thursday night the College Station City Council will consider helping fund a $91 million facility to be built in what's known as the BioCorridor.
Randall Heye, the Economic Development Manager for College Station, says it would be a great asset for the area.
"That agreement would require Kalon to have a $70 million real and personal property evaluation, employ 100 full time equivalents and then also have a payroll of $6 million," he said.
In exchange, the city would refund $1,093,548.61 in property taxes over seven years.
Andrew Strong, the President and CEO of Kalon Biotherapeutics, tells us salaries would average $60,000 for the jobs requiring a bachelor's degree.
"Kalon is a subcontractor to the A&M System under this very large federal contract with the Biomedical Advanced Research Development Authority," said Strong.
By 2020, Strong says people could get flu shots that are being manufactured in College Station through a partnership with GlaxoSmithKline.
"And part of that contract is to grow capacity for influenza vaccine manufacturing as well as manufacturing bio-defense products and other commercial products," he said.
They hope to complete construction by 2016 and eventually have up to 200 new jobs.
The City of Bryan will also have to sign off on their end of an agreement.
College Station's council meeting starts Thursday night at 7.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.